HLA-DQA1 and inflammatory bowel disease: Complementary findings from a recent Oxford study further refined this genetic risk: individuals with IBD who carried HLA-DQA1 05:05 were found to be at an increased risk of developing antibodies against both infliximab and adalimumab, whereas the HLA-DQA1 05:01 allele was associated only with antibody formation against infliximab and not adalimumab [81].